SCHEMBL1607109

SCHEMBL1607109

O=c1c(-c2ccccc2O)c(O)oc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.56
AKR1C3 P42330 1/20 0.54
AKR1C2 P52895 1/20 0.54
AKR1C1 Q04828 1/20 0.54
NTRK1 P04629 1/20 0.53
PLK3 Q9H4B4 1/20 0.53
KDM4E B2RXH2 4/20 0.50
CYP3A4 P08684 4/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
GLA P06280 1/20 0.50
PGAM1 P18669 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NMUR2 Q9GZQ4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1255489 0.89 CYP3A4 (0.57) MAOAAKR1C3AKR1C2AKR1C1NTRK1
SCHEMBL676341 0.83 PTGS2 (0.55) MAOANTRK1PLK3KDM4ECYP3A4
SCHEMBL571524 0.80 MAOA (0.59) MAOAKDM4ECYP3A4HPGDHSD17B10
Daidzein SCHEMBL2308593 0.80 KDM4E (0.64) MAOAKDM4ECYP3A4HPGDHSD17B10
SCHEMBL2318320 0.79 CA1 (0.65) MAOANTRK1PLK3KDM4ECYP3A4
SCHEMBL31675811 0.78 NMUR2 (0.71) MAOAAKR1C3AKR1C2AKR1C1NTRK1
SCHEMBL290080 0.78 NMUR2 (0.71) MAOAAKR1C3AKR1C2AKR1C1NTRK1
SCHEMBL6980060 0.76 PTGS2 (0.61) NTRK1PLK3KDM4ECYP3A4HPGD
SCHEMBL10655426 0.75 MAPK14 (0.59) MAOAKDM4ECYP3A4HPGDHSD17B10
SCHEMBL1180659 0.74 KDM4E (0.62) MAOAKDM4ECYP3A4HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-214020732-U Preparation facilities of 4, 7 dihydroxy isoflavone 四川新一美生物科技有限公司 2021-08-24 CN claimed
EP-2875359-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS Charles R Drew University of Medicine and Science (US) 2015-05-27 EP claimed
WO-2013149258-A2 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME DISORDERS Charles Drew University of Medicine and Science (US) 2013-10-03 WO claimed
EP-1438424-B1 ENZYME SUBSTRATES FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2006-01-18 EP claimed
US-20040259181-A1 detecting beta-D-ribofuranosidase activity using novel chromogenic beta-D-ribofuranoside substrates such as catechol-beta-D-ribofuranoside or 3',4'-dihydroxyflavone-4'-beta-D-dibofuranoside; kits BURTON MICHAEL (GB) 2004-12-23 US claimed
EP-1438424-A2 ENZYME SUBSTRATES FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY Burton, Michael (GB) 2004-07-21 EP claimed
WO-2003035897-A2 ENZYME SUBSTRATES FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2003-05-01 WO claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US disclosed
CN-117384144-A Method for preparing coumarin derivative by photocatalysis three components and application thereof 浙江工业大学 2024-01-12 CN disclosed
CN-117045731-A Pharmaceutical composition for improving estrogen disorder related diseases 哈尔滨医科大学 2023-11-14 CN disclosed
EP-4259316-A2 POLYMERIC MEMBRANE 3M Innovative Properties Company (US) 2023-10-18 EP disclosed
WO-2022123428-A2 POLYMERIC MEMBRANE 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-16 WO disclosed
US-20210330611-A1 THERAPY FOR NEUROLOGICAL DISEASES/DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 US disclosed
EP-1438424-A2 ENZYME SUBSTRATES FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY Burton, Michael (GB) 2004-07-21 EP disclosed
WO-2004009576-A3 MANUFACTURE OF ISOFLAVONES DSM IP ASSETS BV (NL) 2004-05-13 WO disclosed
WO-2004009576-A2 MANUFACTURE OF ISOFLAVONES DSM IP ASSETS B.V. (NL) 2004-01-29 WO disclosed
WO-2003103583-A2 A METHOD FOR USING TETHERED BIS(POLYHYDROXYPHENYLS) AND O-ALKYL DERIVATIVES THEREOF IN TREATING INFLAMMATORY CONDITIONS OF THE CENTRAL NERVOUS SYSTEM OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2003-12-18 WO disclosed
WO-2003035897-A2 ENZYME SUBSTRATES FOR DETECTING BETA-D-RIBOFURANOSIDASE ACTIVITY BURTON MICHAEL (GB) 2003-05-01 WO disclosed
CN-1103231-C Preparation of active material and Chinese medicine preparation for resisting diabetes and its complication SHI HAICHAO (CN) 2003-03-19 CN disclosed
CN-1256140-A Preparation of active material and Chinese medicine preparation for resisting diabetes and its complication SHI HAICHAO (CN) 2000-06-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM S100A8, TP53, AQP1 MAOA 4262/4885AKR1C3 3214/4885AKR1C2 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.